Abstract:Objective: The loss of forkhead box protein O1 (FoxO1) signaling in response to metabolic stress contributes to the etiology of type II diabetes, causing the dedifferentiation of pancreatic beta cells to a cell type reminiscent of endocrine progenitors. Lack of methods to easily model this process in vitro, however, have hindered progress into the identification of key downstream targets and potential inhibitors. We therefore aimed to establish such an in vitro cellular dedifferentiation model and apply it to identify novel agents involved in the maintenance of beta-cell identity. Methods: The murine beta-cell line, Min6, was used for primary experiments and high-content screening. Screens encompassed a library of small-molecule drugs representing the chemical and target space of all FDA-approved small molecules with an automated immunofluorescence readout. Validation experiments were performed in a murine alpha-cell line as well as in primary murine and human diabetic islets. Developmental effects were studied in zebrafish and C. elegans models, while diabetic db/db mouse models were used to elucidate global glucose metabolism outcomes. Results: We show that short-term pharmacological FoxO1 inhibition can model beta-cell dedifferentiation by downregulating beta-cell-specific transcription factors, resulting in the aberrant expression of progenitor genes and the alpha-cell marker glucagon. From a high-content screen, we identified loperamide as a small molecule that can prevent FoxO inhibitor-induced glucagon expression and further stimulate insulin protein processing and secretion by altering calcium levels, intracellular pH, and FoxO1 localization. Conclusions: Our study provides novel models, molecular targets, and drug candidates for studying and preventing beta-cell dedifferentiation.

Acinar to β-like cell conversion through inhibition of focal adhesion kinase

Successful β cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1.

Successful Β Cells Islet Regeneration in Streptozotocin-Induced Diabetic Baboons Using Ultrasound-Targeted Microbubble Gene Therapy with Cyclind2/cdk4/glp1

Successful Β Cells Islet Regeneration Instreptozotocin-Induced Diabetic Baboons Usingultrasound-Targeted Microbubble Gene Therapywith Cyclind2/cdk4/glp1

In Vitro Expansion of Pancreatic Islet Clusters Facilitated by Hormones and Chemicals.

Small Molecules Facilitate the Reprogramming of Mouse Fibroblasts into Pancreatic Lineages

Diabetes treatment by conversion of gut epithelial cells to insulin‐producing cells

Human Expandable Pancreatic Progenitor–derived Β Cells Ameliorate Diabetes

Targeted Pharmacological Therapy Restores Beta-Cell Function For Diabetes Remission

Pancreatic Beta Cell Regeneration Induced By Clinical And Preclinical Agents

Human pancreatic beta-like cells converted from fibroblasts

Lineage Reprogramming: A Promising Road for Pancreatic β Cell Regeneration.

E2F1 transcription factor mediates a link between fat and islets to promote β cell proliferation in response to acute insulin resistance

Insulin-Independent Regulation of Type 1 Diabetes via Brown Adipocyte-Secreted Proteins and the Novel Glucagon Regulator Nidogen-2.

Inhibition of TBK1/IKKε Promotes Regeneration of Pancreatic β-cells

Deletion of Pancreatic Β‐cell Adenosine Kinase Improves Glucose Homeostasis in Young Mice and Ameliorates Streptozotocin‐induced Hyperglycaemia

EZH2 inhibitors promote β-like cell regeneration in young and adult type 1 diabetes donors

An inhibitor-mediated beta-cell dedifferentiation model reveals distinct roles for FoxO1 in glucagon repression and insulin maturation

Functional Analysis Of A Conditionally Transformed Pancreatic Beta-Cell Line

Loss-of-function of ALDH3B2 transdifferentiates human pancreatic duct cells into beta-like cells

Metabolic control of adaptive β-cell proliferation by the protein deacetylase SIRT2